Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 7/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.63 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.63 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.63 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 12/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636979 | 0.91 | KRAS (0.78) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16637040 | 0.89 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128663 | 0.88 | KRAS (0.51) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128537 | 0.88 | KRAS (0.48) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128614 | 0.87 | KRAS (0.51) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23092339 | 0.87 | KRAS (0.81) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16637039 | 0.86 | KRAS (0.50) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL17633422 | 0.86 | KRAS (0.54) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128680 | 0.85 | KRAS (0.50) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16636995 | 0.85 | KRAS (0.53) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021051034-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |